entertainment -WSS

entertainment

author：focus 2025-10-01 20:15:19 - browse：7

Adam's take main illustration — Molly Ferguson/STAT

Annovis Bio had my biotech bull%^&! meter running red after it made a late change to the design of a Phase 3 study in Parkinson’s disease. But then I got an extraordinary explanation from CEO Maria Maccecchini. Now, I’m less worried about data spin because, by her own admission, the odds that the study succeeds, post endpoint change, are a lot lower.

Results from the completed Parkinson’s study, which is investigating Annovis’ drug called buntanetap, are well past due because of what the company has described as ongoing “data cleaning efforts.” The delay was announced on Jan. 24. Two weeks later, on Feb. 6, the primary efficacy endpoint of the study was changed, according to an update posted to the U.S. government’s clinical trials database.

Red flag, I thought, until I emailed Maccecchini, asking for an explanation. In response, she told me Annovis made the key endpoint change in August, based on a recommendation from officials at the Food and Drug Administration after the agency had reviewed data from an interim analysis of the study. It took the company another six months to update the study design in the ClinicalTrials.gov database, for reasons she did not explain.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： ReNAgade cuts staff seven months after raising $300 million

WSS

Pediatric cancer treatments threatened by a new FDA policy

AstraZeneca, Daiichi breast cancer treatment succeeds in trial

Cigna, Humana reportedly in talks to merge

J&J to emphasize cancer drugs, stop much of its vaccine research

CDC director unscathed in first congressional testimony

Despite FDA concern, risk that CAR

explore

entertainment

focus

Medical records are filled with copy

As biotech industry slumps, bioscience job market is upside down

Drug repurposing or repositioning? The language matters

FDA investigates CAR

In Memoriam: Notable people who died in 2023

U.K. Biobank has 500,000 peoples' genome sequences available

BioMarin wins approval for gene therapy to treat hemophilia A

CDC director unscathed in first congressional testimony

In Memoriam: Notable people who died in 2023

Changes to biosimilar regulatory framework must prioritize patients

focus

Flagship Pioneering launches a new biotech in two countries

Organ aging and disease risk measured by new blood test

Senators: Long

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Readout LOUD podcast: possible new ALS drug, artificial wombs

As biotech industry slumps, bioscience job market is upside down

focus

knowledge

Wikipedia

leisure time